Press releases
- RemeGen Showcases Research Results at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, Highlighting Its Prolific Innovation in Global Cancer Treatment
- RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88
- RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren's Syndrome
- RemeGen Celebrates World Lupus Day 2024 with Increased Lupus Visibility through Vital Knowledge Sharing
- RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome
More ▼
Key statistics
On Friday, RemeGen Co Ltd (688331:SHH) closed at 45.68, 36.64% above the 52 week low of 33.43 set on Feb 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 46.74 |
---|---|
High | 46.89 |
Low | 45.43 |
Bid | 45.68 |
Offer | 45.79 |
Previous close | 46.20 |
Average volume | 2.33m |
---|---|
Shares outstanding | 544.33m |
Free float | 307.55m |
P/E (TTM) | -- |
Market cap | 20.72bn CNY |
EPS (TTM) | -2.85 CNY |
Data delayed at least 15 minutes, as of Jun 07 2024.
More ▼